Cargando…
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754738/ https://www.ncbi.nlm.nih.gov/pubmed/28684559 http://dx.doi.org/10.1136/annrheumdis-2017-211734 |
_version_ | 1783290481588830208 |
---|---|
author | Smolen, Josef S Schöls, Monika Braun, Jürgen Dougados, Maxime FitzGerald, Oliver Gladman, Dafna D Kavanaugh, Arthur Landewé, Robert Mease, Philip Sieper, Joachim Stamm, Tanja de Wit, Maarten Aletaha, Daniel Baraliakos, Xenofon Betteridge, Neil van den Bosch, Filip Coates, Laura C Emery, Paul Gensler, Lianne S Gossec, Laure Helliwell, Philip Jongkees, Merryn Kvien, Tore K Inman, Robert D McInnes, Iain B Maccarone, Mara Machado, Pedro M Molto, Anna Ogdie, Alexis Poddubnyy, Denis Ritchlin, Christopher Rudwaleit, Martin Tanew, Adrian Thio, Bing Veale, Douglas de Vlam, Kurt van der Heijde, Désirée |
author_facet | Smolen, Josef S Schöls, Monika Braun, Jürgen Dougados, Maxime FitzGerald, Oliver Gladman, Dafna D Kavanaugh, Arthur Landewé, Robert Mease, Philip Sieper, Joachim Stamm, Tanja de Wit, Maarten Aletaha, Daniel Baraliakos, Xenofon Betteridge, Neil van den Bosch, Filip Coates, Laura C Emery, Paul Gensler, Lianne S Gossec, Laure Helliwell, Philip Jongkees, Merryn Kvien, Tore K Inman, Robert D McInnes, Iain B Maccarone, Mara Machado, Pedro M Molto, Anna Ogdie, Alexis Poddubnyy, Denis Ritchlin, Christopher Rudwaleit, Martin Tanew, Adrian Thio, Bing Veale, Douglas de Vlam, Kurt van der Heijde, Désirée |
author_sort | Smolen, Josef S |
collection | PubMed |
description | Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field. |
format | Online Article Text |
id | pubmed-5754738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-57547382018-02-12 Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force Smolen, Josef S Schöls, Monika Braun, Jürgen Dougados, Maxime FitzGerald, Oliver Gladman, Dafna D Kavanaugh, Arthur Landewé, Robert Mease, Philip Sieper, Joachim Stamm, Tanja de Wit, Maarten Aletaha, Daniel Baraliakos, Xenofon Betteridge, Neil van den Bosch, Filip Coates, Laura C Emery, Paul Gensler, Lianne S Gossec, Laure Helliwell, Philip Jongkees, Merryn Kvien, Tore K Inman, Robert D McInnes, Iain B Maccarone, Mara Machado, Pedro M Molto, Anna Ogdie, Alexis Poddubnyy, Denis Ritchlin, Christopher Rudwaleit, Martin Tanew, Adrian Thio, Bing Veale, Douglas de Vlam, Kurt van der Heijde, Désirée Ann Rheum Dis Recommendation Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field. BMJ Publishing Group 2018-01 2017-07-06 /pmc/articles/PMC5754738/ /pubmed/28684559 http://dx.doi.org/10.1136/annrheumdis-2017-211734 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Recommendation Smolen, Josef S Schöls, Monika Braun, Jürgen Dougados, Maxime FitzGerald, Oliver Gladman, Dafna D Kavanaugh, Arthur Landewé, Robert Mease, Philip Sieper, Joachim Stamm, Tanja de Wit, Maarten Aletaha, Daniel Baraliakos, Xenofon Betteridge, Neil van den Bosch, Filip Coates, Laura C Emery, Paul Gensler, Lianne S Gossec, Laure Helliwell, Philip Jongkees, Merryn Kvien, Tore K Inman, Robert D McInnes, Iain B Maccarone, Mara Machado, Pedro M Molto, Anna Ogdie, Alexis Poddubnyy, Denis Ritchlin, Christopher Rudwaleit, Martin Tanew, Adrian Thio, Bing Veale, Douglas de Vlam, Kurt van der Heijde, Désirée Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title_full | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title_fullStr | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title_full_unstemmed | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title_short | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
title_sort | treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
topic | Recommendation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754738/ https://www.ncbi.nlm.nih.gov/pubmed/28684559 http://dx.doi.org/10.1136/annrheumdis-2017-211734 |
work_keys_str_mv | AT smolenjosefs treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT scholsmonika treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT braunjurgen treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT dougadosmaxime treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT fitzgeraldoliver treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT gladmandafnad treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT kavanaugharthur treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT landewerobert treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT measephilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT sieperjoachim treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT stammtanja treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT dewitmaarten treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT aletahadaniel treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT baraliakosxenofon treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT betteridgeneil treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT vandenboschfilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT coateslaurac treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT emerypaul treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT genslerliannes treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT gosseclaure treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT helliwellphilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT jongkeesmerryn treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT kvientorek treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT inmanrobertd treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT mcinnesiainb treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT maccaronemara treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT machadopedrom treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT moltoanna treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT ogdiealexis treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT poddubnyydenis treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT ritchlinchristopher treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT rudwaleitmartin treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT tanewadrian treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT thiobing treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT vealedouglas treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT devlamkurt treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce AT vanderheijdedesiree treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce |